Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Melanoma 26Neuroblastoma 25Breast Neoplasms 20Prostatic Neoplasms 18Leukemia 15Multiple Myeloma 14Lymphoma 14Leukemia, Myeloid, Acute 14Glioblastoma 14Lymphoma, Non-Hodgkin 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Leukemia, Lymphocytic, Chronic, B-Cell 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms, Male 8Myelodysplastic Syndromes 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Glioma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Fallopian Tube Neoplasms 6Osteosarcoma 5Hodgkin Disease 5Carcinoma, Renal Cell 5Brain Neoplasms 5Uveal Melanoma 4Recurrence 4Rectal Neoplasms 4Medulloblastoma 4

Interventions

Cyclophosphamide 25Temozolomide 22Vincristine 18Irinotecan 18Doxorubicin 13Topotecan 10Melphalan 10Etoposide 10Ifosfamide 8Busulfan 8cabozantinib 7Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Filgrastim 6regorafenib 5fludarabine 5X-Rays 5Specimen Handling 5Sirolimus 5Radiotherapy 5Gemcitabine 5Drug Therapy 5pegfilgrastim 4palbociclib 4liposomal doxorubicin 4irinotecan sucrosofate 4ganitumab 4fludarabine phosphate 4Trabectedin 4Phantoms, Imaging 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT00001564 2019-11-29

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡